Document:

Exhibit
10.13

 

SERVICE
AGREEMENT

 

 

 

This
Independent Contractor Agreement (“Agreement”) is entered into this 27th day of July 2013 between Dr. Wei Ping
Min (“Min”), a research scientist (hereinafter referred to as “Contractor”) whose address is 84 Hesketh
Street, London Ontario N6G5H5, Canada and Regen BioPharma, Inc. (hereinafter referred to as “Client”), a Nevada corporation
with offices at 4700 Spring Street, Suite 304, La Mesa, CA 91942.

 

WHEREAS:

 

	A.  	Contractor
    is a scientific researcher in the area of biological sciences.

 

	B.  	Contractor
    is experienced and knowledgeable with regard to the conducting scientific research in the area of aplastic anemia.

 

NOW
THEREFORE, in consideration of the mutual promises and conditions contained herein, the parties agree as follows:

 

ARTICLE
1

 

Duration
of Contract

 

Section
1.1   This Agreement is effective July 27, 2013 and will continue in effect until June 30, 2014, unless terminated
in accordance with the provisions of Article 7 of this Agreement.

 

Section
1.2   This Agreement may be extended by mutual consent of said parties.

 

ARTICLE
2

 

Independent
Contractor Status

 

Section
2.1   It is the express intention of the parties that Contractor is an independent contractor and not an employee,
agent, joint venture participant, or partner of Client.

 

Nothing
in this Agreement shall be interpreted or construed as creating or establishing the relationship of employer and employee between
Client and Contractor or any employee or agent of Contractor. Both parties acknowledge that Contractor is not an employee for
state or federal tax purposes. Contractor shall retain the right to perform services for others during the term of this Agreement.

 

Section
2.2.  Client acknowledges and agrees that Contractor shall have the right to engage in other independent scientific
activities.

 

 

 

 

ARTICLE
3

 

Services
Performed by Contractor

 

Section
3.1 Participate in discussions with FDA and provide experimental support.

 

Section
3.2 Execution of FDA suggested additional experiment:

 

	(a)  	8-12 week
    female B6 mice will be treated with interperitoneal injection of 150mg/kg 5-FU

 

	(b)  	Groups of
    mice (10 mice per group) will consist of 1) control PBS; 2) 15000 stromal vascular fraction cells; 3) 30000 stromal vascular
    fraction cells; or 4) 60000 stromal vascular fraction cells.

 

	(c)  	Injection
    of stromal vascular fraction cells will be performed intravenously 24 hours after administration of 5-FU

 

	(d)  	Stromal
    vascular fraction cells will either be provided by Regen BioPharma Inc. or isolated according to the protocol Rodriguez et
    al. Int Arch Med. 2012 Feb 8;5: 5

 

	(e)  	Survival
    and complete blood counts will be evaluated every second day over the period of two weeks.

 

	(f)  	Blood Samples
    (20 UL) will be taken retro-orbitally or by tail vein in a vial containing 1 UL of 0.5 M EDTA and white and red cells will
    be calculated.

 

	(g)  	Two weeks
    after injection, animals will be assessed for macroscopic organ changes, and microscopic  histology. Organs analyzed
    will be heart, lung, liver, spleen, kidney and intestine.

 

	(h)  	Histological
    assessment of human Stromal vascular fraction in major organs.

 

Section
3.3 Participate in/perform other experiments that may be requested by FDA for HemaXellerate IND

 

Section
3.4 In vitro development of human dendritic cells and silencing by IDO shRNA

 

	(a)  	Peripheral
    blood mononuclear cells (PBMCs) are isolated as described in the previous Example. A total of 2 X 10(7) PBMCs are cultured
    in 10ml medium per 75cm2 flask (Corning). After 2 hours or overnight the cells are gently agitated and the adherent cells
    are collected. Monocytes (more than 85% CD14+) will be purified from adherent cells by using MACS Monocyte Isolation Kit (Miltenyl
    Biotec, Bergisch Gladbach, Germany), and 1 X 106 cells per millimeter are cultured in 2 ML RPMI 1640, 10% FBS, recombinant
    GM-CSF (rGM-CSF)(10 ng/mL), rlL-4 (500 U/mL) in 6 well flat- bottomed plates.

 

	(b)  	In some
    experiments, tumor necrosis factor-a (TNF-a)(20 ng/mL) is added at the initial culture.

 

	(c)  	IDO targeting
    shRNA will be developed and transfected into generated dendritic cells, control shRNA using scrambled IDO sequences will be
    used.

 

	(d)  	Ability
    of cells to mature will be assessed by flow cytometry for expression of CD83, 80,86, while immaturity as determined by non-differentiation
    will be assessed by the CD14 monocyte marker. In some experiments maturation will be assessed functionally by production of
    IL-10/IL-12 in response to LPS, as well as ability to stimulate allogeneic mixed lymphocyte reaction.

 

 

 

 

	(e)  	Assessment
    of IDO Inhibition will be assessed at the transcript level

 

	(f)  	Standard
    Operating Procedures (SOPs) will be generated for DC maturation and silencing.

 

Section
3.5 Contractor may perform services under this Agreement using Contractor’s own supplies, tools, and instrumentalities or
supplies, tools, and instrumentalities normally provided for on Client’s premises at Contractor’s discretion and expense.

 

ARTICLE
4

 

Compensation

 

Section
4.1 In consideration for services to be performed by Contractor, Client agrees to pay Contractor $100,000 during the 12 month
duration of this contract. There will be 12 total payments made to the contractor ( one twelfth of the $100,000 per month with
the total number of payments aggregating to $100,000)  these payments will be made in Bio-Matrix Scientific Group Inc.’s
common stock (the parent of Regen BioPharma) and will be valued at the closing price on the day before issuance. In the event
of a shortage of available stock to issue for payments owed to Contractor, the amount owed will accrue until the authorized shares
are available to issue to Contractor. These payments will continue for the duration of this contract unless the contract is terminated
under Article 7 of this agreement. All intellectual property developed from this agreement is owned by Regen BioPharma Inc.

 

Section
4.2 The aforementioned common stock in Bio-matrix Scientific Group, Inc. may be issued either as restricted shares or registered
shares at the Company’s discretion.

 

ARTICLE
5

 

Obligations
of Contractor

 

Section
5.1 Contractor agrees to comply with all reasonable requests of Client necessary to the performance of Client’s duties under
this Agreement.  Contractor also agrees to provide access to all pertinent information and documentation necessary to
the performance of his/her services.

 

Section
5.2 Contractor is responsible for his/her own business expenses, including, but not limited to, expenses for travel meals, clothing,
personal equipment and tools, insurance, accounting, etc., that Contractor may incur as a result of performing her services.

 

Section
5.3 Neither this Agreement nor any duties or obligations under this Agreement may be assigned by Contractor without prior
consent of Client.

 

ARTICLE
6

 

Obligations
of Client

 

Section
6.1 Client agrees to comply with all reasonable requests of Contractor necessary to the performance of Contractor’s duties
under this Agreement. Client also agrees to provide access to all pertinent information and documentation necessary to the performance
of his/her services.

 

 

 

 

Section
6.2 Neither this Agreement nor any duties or obligations under this Agreement may be assigned by Client without prior written
consent of Contractor.

 

ARTICLE
7

 

Termination
of Contract

 

Section
7.1 this Agreement shall automatically terminate on the occurrence of any of the following”

 

	A.  	Bankruptcy
    or insolvency of Client

 

	B.  	Sale of
    intellectual property to another entity

 

	C.  	Death or
    incapacitation of Contractor

 

	D.  	Mutual written
    consent of both parties

 

	E.  	In the sole
    determination of the Client, the failure of Contractor to provide any of the duties agreed upon in a skillful, professional
    and workmanlike manner.

 

	F.  	Failure
    of Client to remit payment as agreed herein.

 

	G.  	Regen BioPharma
    ceases to be in the business of biotechnology research and development.

 

Section
8.1 Any notices to be given hereunder by either party to the other party may be effected either by personal delivery in writing
or by mail, registered or certified, postage prepaid with return receipt requested. Mailed notices shall be addressed to the parties
at the addresses appearing in the introductory paragraph of this Agreement, but each party may change the address by written notice
in accordance with this paragraph. Notices delivered personally will be deemed communicated as of actual receipt; mailed notices
will be deemed communicated as of three days after mailing.

 

Section
8.2 This Agreement supersedes any and all agreements , either oral or written, between the parties hereto with respect to the
rendering of services by Contractor to Client and contains all the covenants and agreements between the parties with respect to
the rendering of such services in any manner whatsoever. Each party to this Agreement acknowledges that no promises, or agreement,
orally or otherwise, have been made by any party, or anyone acting on behalf of any party, that are not embodied herein, and that
no agreement, statement or promise not contained in this Agreement shall be valid or binding. Any modification to this Agreement
will be effective only if it is in writing signed by the parties hereto.

 

Section
8.3 if any provision of this Agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable, the
remaining provisions will nevertheless continue in full force without being impaired or invalidated in any way.

 

Section
8.4 If any action at law or inequity, including an action for declaratory relief, is brought to enforce or interpret the provisions
of this Agreement, the prevailing party will be entitled to reasonable attorney’s fees, which may be set by the court in
the same action or in a separate action brought for that purpose, in addition to any other relief to which the party may be entitled.

 

Section
8.5 This Agreement will be governed by the laws of the State of California.

 

 

 

 

IN
WITNESS WHEREOF, this contract is executed in the City of San Diego, County of San Diego, State of California, on the date and
year first above written.

 

  

CONTRACTOR

 

/s/Wei
Ping Min                        

Wei
Ping Min, MD, PhD

Independent
Contractor

 

  

CLIENT

 

/s/David
R. Koos                       

By:
David R Koos

Its:
Chairman and CEO

Regen
BioPharma Inc.Exhibit
10.14

 

This
SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of , by and between Regen Biopharma, Inc. , a Nevada corporation,
with headquarters located at 4700 Spring Street, Suite 304,La Mesa California, 91942, (the “Company”), and ASC Recap
LLC, a Connecticut Limited Liability Company, with its address at 90 Grove Street, Suite 108, Ridgefield CT 06877(the “Buyer”).

 

WHEREAS:

 

A.The
Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”);

B.Buyer
desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement 100,000
shares of common stock, $0.0001 par value per share, of the Company (the “Common Stock”).

NOW
THEREFORE, the Company and the Buyer hereby agree as follows:

 

1.Purchase
and Sale of the Common Stock.

a.
Purchase of the Common Stock. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer
agrees to purchase from the Company the Common Stock

b.
Form of Payment. On the Closing Date (as defined below), (i) the Buyer shall pay the amount of $ 100,000 USD for the Common Stock
to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately
available funds to the Company, in accordance with the Company’s written wiring instructions and (ii) the Company shall
deliver the Common Stock to the Buyer, against delivery of such Purchase Price.

c.
Closing Date. The date and time of the issuance and sale of the Common Stock pursuant to this Agreement (the “Closing Date”)
shall be September 30, 2013 , or such other mutually agreed upon time. The closing of the transactions contemplated by this Agreement
(the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

 

2.
Buyer’s Representations and Warranties. The Buyer represents and warrants to the Company that:

a.Investment
Purpose. As of the date hereof, the Buyer is purchasing the shares of Common Stock for its own account and not with a present
view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under
the 1933 Act

b.Accredited
Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an
“Accredited Investor”).

c.Reliance
on Exemptions. The Buyer understands that the Common Stock is being offered and sold to it in reliance upon specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the
truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and
understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of
the Buyer to acquire the Common Stock.

d.
Information .The Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and
operations of the Company and materials relating to the offer and sale of the Common Stock which have been requested by the Buyer
or its advisors. The Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Notwithstanding
the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information
unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer.

e.
Transfer or Re-sale. The Buyer understands that sale or re-sale of the Common Stock has not been and is not being registered under
the 1933 Act or any applicable state securities laws, and the Common Stock may not be offered, sold, transferred, pledged, hypothecated
or otherwise disposed of except pursuant to an effective registration statement under the 1933 Act and applicable state securities
laws or any other applicable securities laws or pursuant to an applicable exemption from the registration requirements of such
1933 Act and such laws;

f.
Legends. The Buyer understands that the Common Stock will bear a restrictive legend in substantially the following form:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

g.
Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered
on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with
its terms.

 

3.
Company’s Representations and Warranties. The Company represents and warrants to the Buyer that:

a.
Organization. Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada
and has the corporate power and authority to carry on its business as it is now being conducted.

b.
Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered
on behalf of the Company, and this Agreement constitutes a valid and binding agreement of the Company enforceable in accordance
with its terms.

 

4.
General Provisions.

a.
Entire Agreement. This Agreement constitutes the entire Agreement and supersedes all prior agreements and understandings, oral
and written, between the parties hereto with respect to the subject matter hereof.

b.
Governing Law. This Agreement, and all transactions contemplated hereby, shall be governed by, construed and enforced in accordance
with the laws of the State of California. In the event that litigation results from or arises out of this Agreement or the performance
thereof, the parties agree to reimburse the prevailing party's reasonable attorney's fees, court costs, and all other expenses,
whether or not taxable by the court as costs, in addition to any other relief to which the prevailing party may be entitled.

 

 

IN
WITNESS WHEREOF, this Agreement has been executed by each of the individual parties hereto on the date first above written.

 

Signed,
sealed and delivered in the presence of:

 

COMPANY:

By:
   /s/David R. Koos                                           Date signed:9/30/2013

David
R. Koos, Chairman and CEO

 

BUYER

By:
   Stephen Hicks                                                Date signed: 9/30/2013

Stephen
Hicks, Managing Partner

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]